NASHUA, N.H., Nov. 10, 2016 (GLOBE NEWSWIRE) -- iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will present at two investor conferences in November 2016. The first presentation will be at the 7 th Annual Craig-Hallum Alpha Select Conference in New York, NY. Event: 7 th Annual Craig-Hallum Alpha Select Conference Dates: Wednesday, November 16, 2016 Time: 1:30 pm ET The second presentation will be at the Canaccord Genuity Medical Technologies & Diagnostics Forum in New York, NY. Event: Canaccord Genuity Medical Technologies & Diagnostics Forum Dates: Thursday, November 17, 2016 Time: 1:20 pm ET Audio webcasts of the Company's presentations will be available online at www.icadmed.com. Replays of the presentations will be available for 90 days. About iCAD, Inc. iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer-aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.